Article Dans Une Revue JAMA oncology Année : 2020

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

Hugues Talbot

Résumé

Question: Are the different definitions used to assess HPD representative of a same tumoral behaviour? Findings: For this multicentre cohort study including 406 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors, the different definitions resulted in diverse incidences, patients' characteristics and correlations with survival outcomes. Meaning: The 5 definitions are not representative of a same tumoral behaviour. We defined a new criteria ΔTGR > 100 that looks more accurate assessing HPD.

Fichier principal
Vignette du fichier
Article definitions HPD.pdf (1.04 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-03144929 , version 1 (19-02-2021)

Licence

Identifiants

Citer

Baptiste Kas, Hugues Talbot, Roberto Ferrara, Colombe Richard, Jean-Philippe Lamarque, et al.. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer. JAMA oncology, 2020, 6 (7), pp.1039. ⟨10.1001/jamaoncol.2020.1634⟩. ⟨hal-03144929⟩
320 Consultations
517 Téléchargements

Altmetric

Partager

  • More